前列腺癌中VEGF和COX-2的表达及临床意义  

Expression and Clinical Significance of VEGF and COX-2 in Prostate Cancer

作　　者：史玉爽[1] 杨媚[2] 肖胜[1] 

机构地区：[1]荆州市第一人民医院,湖北荆州434000 [2]荆州市精神卫生中心特检科,湖北荆州434000

出　　处：《黑龙江医学》2015年第9期1046-1048,共3页Heilongjiang Medical Journal

摘　　要：目的通过检测VEGF和COX-2在前列腺癌组织及前列腺增生组织中的表达情况,从而探讨两者与前列腺癌发生发展的关系。方法采用免疫组化SP方法检测前列腺癌组织及前列腺增生组织中两者的表达情况,比较两者在两种不同组织中的表达情况。结果前列腺癌组织中,VEGF的表达阳性率为64.00%(32/50),在前列腺增生组织中VEGF的表达阳性率为15.0%(3/20),VEGF在前列腺癌组织及前列腺增生组织中表达阳性率差异性显著(P<0.05);COX-2在前列腺癌组织中的表达阳性率为68.00%(34/50),在前列腺增生组织中的阳性表达率为20.00%(4/20),COX-2在前列腺癌组织及前列腺增生组织中表达阳性率差异性显著(P<0.05);VEGF的表达水平与肿瘤的分化程度、临床分期密切相关;COX-2与肿瘤的临床分期相关,但是与分化程度无明显关系。结论 VEGF与COX-2与前列腺癌的发生及发展密切相关,通过检测VEGF与COX-2的表达水平预测前列腺癌患者的预后情况,为临床上治疗前列腺癌提供一定的理论根据,因此也可以为临床上对前列腺癌的后续治疗提供一定的指导方法。Objective To detect VEGF and COX -2 in prostate cancer and benign prostatic hyperplasia tissues, and thereby to explore the relationship between the development of prostate cancer. Methods [mmunohistochemical SP method was used to detect prostate cancer and benign prostatic hyperplasia tissue expression, and the expression of both was compared in the two different tissues. Results In pros- tate cancer, VEGF expression positive rate was 64. 00% （32/50）. In BPH tissue, VEGF expression positive rate was 15.0% （3/20）. There was significantly difference in positive rate of VEGF expression in prostate cancer and benign prostatic hyperplasia tissue （P 〈 0.05 ）. COX -2 in prostate cancer tissue expression was 68.00% （34/50）. The positive expression in benign prostatic hyperplasia tis- sue was 20. 00% （4/20）. In COX- 2 expression in prostate cancer and benign prostatic hyperplasia, the positive rate was significantly difference （ P 〈 0.05 ）. The expression of VEGF was closely related with tumor differentiation and TNM stage. COX - 2 was correlated with the clinical stage of the tumor, but there was no significant relationship between the degrees of differentiation. Conclusion VEGF and COX - 2 is closely related to the occurrence and development of prostate cancer by detecting the expression of VEGF and COX - 2 in predie- ting the prognosis of patients with prostate cancer to provide theoretical basis for the clinical treatment of prostate cancer, and therefore it may provide some guidance methods of clinical follow - up treatment for prostate cancer.

关 键 词：前列腺癌 前列腺增生组织 血管内皮生长因子 环氧化酵素二型 

分 类 号：R737.25[医药卫生—肿瘤]